Skip to content
Sickle Cell Disease News logo
  • About sickle cell disease
    What is sickle cell disease?
    Causes
    Living with sickle cell disease
    Symptoms
    • Vaso-occlusive crisis
    Diagnosis
  • Treatments
    Approved treatments
    Experimental treatments
    Non-drug treatments
  • News
  • Columns
    Shaniqua’s Sickle Chronicles — Mary Shaniqua
    The Sickle Cell Crusader – Oluwatosin Adesoye
    Sickle Sagas — Dunstan Nicol-Wilson
    Sickle Unshackled – Sylvia Amuta
    Archived columns
    • Her Sickled Journey — Tito Oye
    • I Sickle Well — Somi Igbene
  • Forums
  • What can we help you find today?

June 5, 2025 News by Steve Bryson, PhD

Oral inhibitor rilzabrutinib granted FDA orphan drug status for SCD

The U.S. Food and Drug Administration has granted orphan drug status to Sanofi’s rilzabrutinib, an investigational therapy aimed at preventing painful vaso-occlusive crises (VOCs) in people with sickle cell disease (SCD). This designation intends to encourage companies to develop therapies for rare diseases, or those affecting fewer…

June 13, 2018 News by Margarida Azevedo, MSc

Potential Treatment Targeting Nitric Oxide Levels, Olinciguat, Named Orphan Drug by FDA

The U.S. Food and Drug Administration (FDA) recently granted orphan drug status to olinciguat (IW-1701) as a potential treatment of sickle cell disease (SCD), Ironwood Pharmaceuticals announced. Evidence suggests that the symptoms of sickle cell disease may be associated with nitric oxide deficiency in the blood. Nitric oxide…

April 10, 2018 News by Margarida Azevedo, MSc

Altemia Granted Orphan Drug Status in EU as Potential Therapy for Pediatric Sickle Cell Disease

The European Medicines Agency recently granted orphan drug status to Sancilio Pharmaceuticals’ Altemia for the treatment of sickle cell disease (SCD) in pediatric patients, the company announced. Altemia is a specific formulation of lipids designed to replenish the elements needed for healthy red blood cells that are damaged…

May 16, 2017 News by Joana Fernandes, PhD

Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease Designation

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to IMR-687, Imara’s drug candidate for the treatment of sickle cell disease (SCD). The investigational therapy has also been granted orphan drug status by the FDA. Rare pediatric disease designation is granted to drugs that show promise…

Recent Posts

  • Oral inhibitor rilzabrutinib granted FDA orphan drug status for SCD
  • Malaria prevention is crucial to sickle cell disease management
  • Algorithm helps reduce unneeded hospital stays for sickle cell children
  • Access to physical therapy may be issue for young sickle cell patients
  • High mortality from pneumococcal meningitis seen for SCD children
  • Let’s explore the different types of sickle cell crisis
  • My thoughts on recovery, 3 days after a sickle cell pain crisis
  • Low use of primary care, depression screenings by teens with sickle cell
  • Comprehensive SCD care may reduce emergency visits for adults
  • SCD, sickle cell trait may increase risk of diabetic eye disease: Study


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.